| 货号 | 31122S |
| 反应种属 | Mouse |
| 来源宿主 | Rabbit |
| 应用 | WB |
| 目标/特异性 | Phospho-RIP (Ser166) Antibody (Rodent Specific) recognizes endogenous levels of mouse RIP protein only when phosphorylated at Ser166. A nonspecific band is observed at 22 kDa. |
| 使用方法 | W |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | The receptor-interacting protein (RIP) family of serine-threonine kinases (RIP, RIP2, RIP3, and RIP4) are important regulators of cellular stress that trigger pro-survival and inflammatory responses through the activation of NF-κB, as well as pro-apoptotic pathways (1). In addition to the kinase domain, RIP contains a death domain responsible for interaction with the death domain receptor Fas and recruitment to TNF-R1 through interaction with TRADD (2,3). RIP-deficient cells show a failure in TNF-mediated NF-κB activation, making the cells more sensitive to apoptosis (4,5). RIP also interacts with TNF-receptor-associated factors (TRAFs) and can recruit IKKs to the TNF-R1 signaling complex via interaction with NEMO, leading to IκB phosphorylation and degradation (6,7). Overexpression of RIP induces both NF-κB activation and apoptosis (2,3). Caspase-8-dependent cleavage of the RIP death domain can trigger the apoptotic activity of RIP (8). |
| 存放说明 | -20C |
| 计算分子量 | 80 |
| 参考文献 | 1 . Meylan, E. and Tschopp, J. (2005) Trends Biochem Sci 30, 151-9. 2 . Hsu, H. et al. (1996) Immunity 4, 387-96. 3 . Stanger, B.Z. et al. (1995) Cell 81, 513-23. 4 . Ting, A.T. et al. (1996) EMBO J 15, 6189-96. 5 . Kelliher, M.A. et al. (1998) Immunity 8, 297-303. 6 . Devin, A. et al. (2000) Immunity 12, 419-29. 7 . Zhang, S.Q. et al. (2000) Immunity 12, 301-11. 8 . Lin, Y. et al. (1999) Genes Dev 13, 2514-26. 9 . Christofferson, D.E. and Yuan, J. (2010) Curr Opin Cell Biol 22, 263-8. 10 . Kaczmarek, A. et al. (2013) Immunity 38, 209-23. 11 . Degterev, A. et al. (2008) Nat Chem Biol 4, 313-21. 12 . Degterev, A. et al. (2005) Nat Chem Biol 1, 112-9. 13 . Ofengeim, D. and Yuan, J. (2013) Nat Rev Mol Cell Biol 14, 727-36. |
Western blot analysis of L-929 cells, untreated (-) or treated with combinations of the following treatments as indicated: Z-VAD (20 μM, added 30 min prior to other compounds; +), MouseHis6 Tumor Necrosis Factor-α #4698 (mTNF-α, 20 ng/ml, 2 hr; +), SM-164 (100 nM, 2 hr; +), and necrostatin-1 (Nec-1, 50 μM, 2 hr; +), using Phospho-RIP (Ser166) (Rodent Specific) Antibody (upper) or β-Actin (D6A8) Rabbit mAb #8457 (lower). |
